Literature DB >> 882479

Interaction between warfarin and sulphamethoxazole.

W J Tilstone, J M Gray, R H Nimmo-Smith, D H Lawson.   

Abstract

A patient is described in whom there was strong circumstantial evidence of an interaction between warfarin and co-trimaxazole. To test the validity of this hypothesis a series of in vitro and in vivo human studies were untaken. The results indicate that interaction may occur in which the sulphamethoxazole moiety of co-trimoxazole displaces warfarin from its binding sites on plasma albumin. Nevertheless, this interaction occurs only at high plasma levels of warfarin and is most likely to be clinically significant only in patients receiving high doses of warfarin who have low plasma albumin concentrations. These studies indicate that the use of co-trimoxazole is not contra-indicated in patients receiving warfarin therapy, but care should be exercised, especially in patients with high plasma warfarin:albumin ratios.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 882479      PMCID: PMC2496689          DOI: 10.1136/pgmj.53.621.388

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  9 in total

1.  Anticoagulant resistance: an unusual case.

Authors:  D B Barnett; B W Hancock
Journal:  Br Med J       Date:  1975-03-15

2.  Prothrombin response to phenindione during hypoalbuminaemia.

Authors:  D R Varma; R K Gupta; S Gupta
Journal:  Br J Clin Pharmacol       Date:  1975-10       Impact factor: 4.335

3.  Changes in drug metabolism with increasing age: 1. warfarin binding and plasma proteins.

Authors:  M J Hayes; M J Langman; A H Short
Journal:  Br J Clin Pharmacol       Date:  1975-02       Impact factor: 4.335

4.  Sulfamethizole-induced inhibition of diphenlhydantoin, tolbutamide, and warfarin metabolism.

Authors:  B Lumholtz; K Siersbaek-Nielsen; L Skovsted; J Kampmann; J M Hansen
Journal:  Clin Pharmacol Ther       Date:  1975-06       Impact factor: 6.875

Review 5.  Drug interactions with coumarin anticoagulants. 2.

Authors:  J K Weser; E Sellers
Journal:  N Engl J Med       Date:  1971-09-02       Impact factor: 91.245

6.  A rapid method for the estimation of drug-albumin affinity constants in human plasma.

Authors:  H M Solomon; G B Thomas
Journal:  Clin Pharmacol Ther       Date:  1971 May-Jun       Impact factor: 6.875

7.  The effect of various drugs on the binding of warfarin-14C to human albumin.

Authors:  H M Solomon; J J Schrogie
Journal:  Biochem Pharmacol       Date:  1967-07-07       Impact factor: 5.858

8.  Rapid fluorometric assay for plasma warfarin.

Authors:  M Corn; R Berberich
Journal:  Clin Chem       Date:  1967-02       Impact factor: 8.327

9.  Displacement of warfarin from human albumin by diazoxide and ethacrynic, mefenamic, and nalidixic acids.

Authors:  E M Sellers; J Koch-Weser
Journal:  Clin Pharmacol Ther       Date:  1970 Jul-Aug       Impact factor: 6.875

  9 in total
  6 in total

Review 1.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

2.  Lack of effect of co-trimoxazole on the pharmacokinetics and pharmacodynamics of nifedipine.

Authors:  C Edwards; S Monkman; S Cholerton; M D Rawlins; J R Idle; R E Ferner
Journal:  Br J Clin Pharmacol       Date:  1990-12       Impact factor: 4.335

Review 3.  Drug interactions that matter. A critical reappraisal.

Authors:  G T McInnes; M J Brodie
Journal:  Drugs       Date:  1988-07       Impact factor: 9.546

Review 4.  Clinically significant drug interactions with the oral anticoagulants.

Authors:  M D Freedman; A G Olatidoye
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

5.  Clinical pharmacokinetics of co-trimoxazole (trimethoprim-sulphamethoxazole).

Authors:  R B Patel; P G Welling
Journal:  Clin Pharmacokinet       Date:  1980 Sep-Oct       Impact factor: 6.447

Review 6.  Clinical pharmacokinetic considerations in the elderly. An update.

Authors:  S Dawling; P Crome
Journal:  Clin Pharmacokinet       Date:  1989-10       Impact factor: 6.447

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.